arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Protalix BioTherapeutics, Inc.

PLX
$2.51 ▼ -0.17 (-6.34%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protalix BioTherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $200.8M
Dividend Yield —
Revenue Growth 27.1% ↘
Op. Margin 23.5% ↘
ROIC 5.1% ↘
FCF / Share $-0.14 ↘
Trailing P/E 50.2x
Price / Book 2.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.90M
↑ +27.1% —
Net Income Profit after all expenses
$3.78M
↑ +2203.0% —
Operating Margin Operating profit as % of sales
23.5%
↓ -62.5% 15th
FCF / Share Free cash flow per share
$-0.14
↓ -90.9% —
Long-Term Debt Long-term obligations
$376.00K
↓ -86.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
12
Returns
31
Cash Quality ↑
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters